Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SY-1365 |
Synonyms | |
Therapy Description |
SY-1365 is a selective CDK7 inhibitor that induces apoptosis in tumor cells (PMID: 31064851, PMID: 32150405). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SY-1365 | SY1365 | CDK7 Inhibitor 16 | SY-1365 is a selective CDK7 inhibitor that induces apoptosis in tumor cells (PMID: 31064851, PMID: 32150405). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03134638 | Phase I | Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Terminated | USA | FRA | CAN | 0 |